Investor Presentaiton

IDE397 Phase 1/2 Clinical Development Plan Clinical Strategy Focus on Select Monotherapy and High Conviction Combination IDE397 Development Candidate - Clinical Profile • Exposure-Dependent Pharmacokinetic (PK) Profile with low Cmax:Cmin • Robust, Exposure-Dependent Pharmacodynamic (PD) Response Monotherapy Expansion showing Clinical Efficacy - with Responses in Multiple High-Priority Tumor Types early in Dose Expansion, including a confirmed PR IDE397 is uniquely positioned to evaluate efficacy in MTAP pathway, with a favorable PK/PD profile and observed therapeutic window Mono Expansion in Select MTAP-null Tumor Histologies IDE397 RDE Mono Expansion Basket: NSCLC, Esophageal, Gastric, Bladder Focus or Additional Indication Expansion Combination Cohorts - Clinical Proof of Concept in MTAP-null Tumors AMGEN IDE397 + AMG 193 MTA-Cooperative PRMT5i#^: Solid Tumors Other Potential Indications or Combinations Addressable Patient Population of ~50,000 estimated in US, EU5 and JP across priority tumors - NSCLC, bladder, gastric, and esophageal cancers # AMG193 = Amgen's investigational MTA-cooperative PRMT5 inhibitor 28 ^ Amgen reported that initial data for AMG 193 monotherapy expansion demonstrated responses in multiple tumor types (See Amgen earnings release and corporate presentation dated August 3, 2023) IDEAVA BIOSCIENCES

View entire presentation